Man Group PLC Bristol Myers Squibb CO Transaction History

Man Group PLC

$36 Billion
Q3 2024

A detailed history of Man Group PLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Man Group PLC holds 3,230,012 shares of BMY stock, worth $187 Million. This represents 0.46% of its overall portfolio holdings.

Number of Shares

3,230,012

Previous 4,688,898 31.11%

Holding current value

$187 Million

Previous $195 Million 14.16%

% of portfolio

0.46%

Previous 0.52%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$39.66 - $51.75 $57.9 Million - $75.5 Million	-1,458,886 Reduced 31.11%	3,230,012 $167 Million
Q2 2024 Aug 14, 2024	BUY	$40.25 - $52.99 $115 Million - $152 Million	2,862,266 Added 156.7%	4,688,898 $195 Million
Q1 2024 May 15, 2024	SELL	$47.98 - $54.4 $17.6 Million - $20 Million	-367,843 Reduced 16.76%	1,826,632 $99.1 Million
Q4 2023 Feb 14, 2024	BUY	$48.48 - $57.85 $93.5 Million - $112 Million	1,928,443 Added 724.89%	2,194,475 $113 Million
Q3 2023 Nov 14, 2023	SELL	$57.89 - $64.73 $14.6 Million - $16.4 Million	-252,840 Reduced 48.73%	266,032 $15.4 Million
Q2 2023 Aug 14, 2023	BUY	$63.71 - $70.74 $3.25 Million - $3.61 Million	50,962 Added 10.89%	518,872 $33.2 Million
Q1 2023 May 15, 2023	SELL	$65.71 - $74.53 $22.9 Million - $25.9 Million	-348,055 Reduced 42.66%	467,910 $32.4 Million
Q4 2022 Feb 14, 2023	BUY	$68.48 - $81.09 $14 Million - $16.6 Million	205,055 Added 33.57%	815,965 $58.7 Million
Q3 2022 Nov 14, 2022	BUY	$0.13 - $76.84 $37,071 - $21.9 Million	285,167 Added 87.54%	610,910 $43.4 Million
Q2 2022 Aug 15, 2022	BUY	$72.62 - $79.98 $7.69 Million - $8.47 Million	105,861 Added 48.14%	325,743 $25.1 Million
Q1 2022 May 16, 2022	SELL	$61.48 - $73.72 $27.6 Million - $33.1 Million	-449,357 Reduced 67.14%	219,882 $16.1 Million
Q4 2021 Feb 14, 2022	SELL	$53.63 - $62.52 $32.3 Million - $37.6 Million	-601,842 Reduced 47.35%	669,239 $41.7 Million
Q3 2021 Nov 15, 2021	BUY	$59.17 - $69.31 $25.9 Million - $30.3 Million	437,622 Added 52.51%	1,271,081 $75.2 Million
Q2 2021 Aug 16, 2021	SELL	$61.91 - $67.42 $68.7 Million - $74.8 Million	-1,109,122 Reduced 57.1%	833,459 $55.7 Million
Q1 2021 May 17, 2021	SELL	$59.34 - $66.74 $84.6 Million - $95.2 Million	-1,425,757 Reduced 42.33%	1,942,581 $123 Million
Q4 2020 Feb 16, 2021	SELL	$57.74 - $65.43 $45 Million - $51 Million	-779,926 Reduced 18.8%	3,368,338 $209 Million
Q3 2020 Nov 16, 2020	BUY	$57.43 - $63.64 $33.5 Million - $37.2 Million	583,812 Added 16.38%	4,148,264 $250 Million
Q2 2020 Aug 14, 2020	BUY	$54.82 - $64.09 $133 Million - $156 Million	2,427,666 Added 213.56%	3,564,452 $210 Million
Q1 2020 May 15, 2020	SELL	$46.4 - $67.43 $43.8 Million - $63.7 Million	-944,052 Reduced 45.37%	1,136,786 $63.4 Million
Q4 2019 Feb 18, 2020	BUY	$49.21 - $64.19 $78.3 Million - $102 Million	1,591,579 Added 325.3%	2,080,838 $134 Million
Q3 2019 Nov 14, 2019	SELL	$42.77 - $50.71 $58.4 Million - $69.3 Million	-1,366,433 Reduced 73.63%	489,259 $24.8 Million
Q2 2019 Aug 14, 2019	SELL	$44.62 - $49.34 $43.1 Million - $47.6 Million	-965,384 Reduced 34.22%	1,855,692 $84.2 Million
Q1 2019 May 15, 2019	SELL	$45.12 - $53.8 $35.3 Million - $42.1 Million	-782,118 Reduced 21.71%	2,821,076 $135 Million
Q4 2018 Feb 14, 2019	BUY	$48.76 - $63.23 $87.1 Million - $113 Million	1,786,780 Added 98.37%	3,603,194 $187 Million
Q3 2018 Nov 14, 2018	BUY	$55.19 - $62.25 $40.7 Million - $45.9 Million	737,891 Added 68.42%	1,816,414 $113 Million
Q2 2018 Aug 14, 2018	BUY	$50.53 - $62.98 $40.3 Million - $50.3 Million	797,899 Added 284.33%	1,078,523 $59.7 Million
Q1 2018 May 15, 2018	BUY	$59.92 - $68.98 $16.8 Million - $19.4 Million	280,624 New	280,624 $17.8 Million

Others Institutions Holding BMY

# of Institutions

2,536

Shares Held

1.47B

Call Options Held

31.6M

Put Options Held

35M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $123B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.

Account